Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
Conditions: Colorectal Cancer; Minimal Residual Disease Interventions: Drug: Fludarabine Phosphate; Drug: Cyclophosphamide; Drug: Cetuximab; Drug: TROP2-CAR-NK Cells; Drug: Rimiducid (AP1903); Procedure: Lymphodepleting Chemotherapy Sponsors: M.D. Anderson Cancer Center; Bellicum Pharmaceuticals, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
The Man Van Project
Conditions: Prostate Cancer; Urologic Cancer; Urologic Diseases; Bladder Cancer; Diabetes; Hypertension; Mental Health Issue; Alcoholism; Smoking; Renal Cancer; Testis Cancer Interventions: Device: MV-POCT Sub-study; Other: Main Man Van Group Sub-study; Other: MV-QualQ Sub-study; Diagnostic Test: MV-PRS Sub-study; Other: MV-DNA and MV-UctDNA Sub-study; Other: Man Van patients Sponsors: Royal Marsden NHS Foundation Trust; RM Partners West London Cancer Alliance; Institute of Cancer Research, United Kingdom; Imperial College London Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Adapting Enhanced Recovery Programs for Low Health Literacy Patients
Conditions: Surgery; Health Knowledge, Attitudes, Practice; Colorectal Disorders Interventions: Other: Educational intervention (VISACT) Sponsors: University of Alabama at Birmingham; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma
Conditions: Mantle Cell Lymphoma Interventions: Procedure: Biospecimen Collection; Procedure: Bone Marrow Biopsy; Procedure: Computed Tomography; Procedure: Echocardiography; Procedure: FDG-Positron Emission Tomography; Biological: Glofitamab; Drug: Ibrutinib; Procedure: Magnetic Resonance Imaging; Biological: Obinutuzumab Sponsors: OHSU Knight Cancer Institute; Oregon Health and Science University; Genentech, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical Cystectomy
Conditions: Bladder Cancer; Bladder Cancer Stage I; Bladder Cancer Stage II Interventions: Drug: Cisplatin Sponsors: Ankara Etlik City Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors
Conditions: Desmoid Tumor; Desmoid Fibromatosis; Desmoid Interventions: Procedure: radiofrequency ablation Sponsors: Blokhin ' s Russian Cancer Research Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Time From PCI to Cancer Surgery and Cardiovascular and Oncologic Outcomes
Conditions: Coronary Artery Disease; Cancer Sponsors: Samsung Medical Center Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Sintilimab Combined With Fruquintinib/Regorafenib ± Radiotherapy for Third-line Treatment of Advanced Metastatic Colorectal Cancer
Conditions: Colorectal Cancer; Immunotherapy; Radiotherapy; Targeted Therapy Interventions: Drug: Sintilimab Sponsors: Shandong Cancer Hospital and Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma
Conditions: Invasive Breast Cancer Interventions: Other: no intervention Sponsors: Marwa Mahmoud Hassan; Qena Oncology Center Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status
Conditions: Colorectal Cancer; Colorectal Neoplasms Interventions: Drug: Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens Sponsors: Sun Jing Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer
Conditions: Urothelial Carcinoma Interventions: Drug: Enfortumab vedotin; Drug: Pembrolizumab Sponsors: University of Michigan Rogel Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
A Risk Prediction Model of Postoperative Nausea and Vomiting in Patients With Liver Cancer
Conditions: Nausea and Vomiting, Postoperative; Liver Cancer Interventions: Other: 1 Sponsors: Shanghai Zhongshan Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Conditions: Non-Small Cell Lung Cancer Interventions: Drug: Datopotamab Deruxtecan; Drug: Rilvegostomig; Drug: Pembrolizumab Sponsors: AstraZeneca; Daiichi Sankyo Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial
Conditions: Colorectal Cancer Interventions: Drug: Tislelizumab with Fruquintinib, Metronidazole Sponsors: Jing-yuan Fang, MD, Ph. D Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Role of Renal Biopsy in the Suspicion of Nephrotoxicity of Immunotherapy (Checkpoint Inhibitors) in Solid Cancer
Conditions: Chemotherapeutic Toxicity Interventions: Other: No intervention Sponsors: Central Hospital, Nancy, France; University Hospital, Strasbourg, France; CHU de Reims; Centre Hospitalier R égional Metz-Thionville; European Georges Pompidou Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
